Mirum Pharmaceuticals MIRM
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Mirum Pharmaceuticals (MIRM) Core Market Data and Business Metrics
Latest Closing Price
$45Price-Earnings Ratio
-24.32Total Outstanding Shares
49.01 Million SharesDividend
No dividendSIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
989 East Hillsdale Boulevard, Suite 300, Foster City, CA, 94404
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 536,478 Shares | 11.71 | 3/14/2025 | 6,282,518 Shares |
| 666,028 Shares | 9.95 | 2/28/2025 | 6,626,034 Shares |
| 449,799 Shares | 14.69 | 2/14/2025 | 6,608,635 Shares |
| 531,270 Shares | 12.37 | 1/31/2025 | 6,573,423 Shares |
| 492,622 Shares | 13.5 | 1/15/2025 | 6,649,342 Shares |
| 375,524 Shares | 17.12 | 12/31/2024 | 6,430,289 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities | $17.70 Million |
| Net Cash Flow From Investing Activities | $-90.13 Million |
| Net Cash Flow | $-62.10 Million |
| Net Cash Flow From Operating Activities | $10.32 Million |
| Net Cash Flow From Operating Activities, Continuing | $10.32 Million |
| Net Cash Flow From Financing Activities, Continuing | $17.70 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Operating Expenses | $424.49 Million |
| Income/Loss From Continuing Operations After Tax | $-87.94 Million |
| Income Tax Expense/Benefit, Deferred | $0 |
| Basic Earnings Per Share | $-1.85 |
| Net Income/Loss | $-87.94 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $-89.96 Million |
| Comprehensive Income/Loss | $-89.96 Million |
| Other Comprehensive Income/Loss | $-2.02 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Current Liabilities | $79.69 Million |
| Equity Attributable To Parent | $225.64 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
| Noncurrent Liabilities | $318.56 Million |
| Other Current Assets | $370.38 Million |
| Current Liabilities | $126.55 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||